Cabaletta Bio (CABA) Cash from Operations (2018 - 2025)
Cabaletta Bio (CABA) posted quarterly Cash from Operations of 35343000.0 for Q4 2025, down 52.85% year-over-year from 74965677.09 in Q4 2024, and down 2.42% quarter-over-quarter from 34509000.0 in Q3 2025.
Cabaletta Bio (CABA) Cash from Operations (2018 - 2025) Analysis & Trends
Cabaletta Bio's Cash from Operations history runs 8 years deep, the most recent figure standing at 35343000.0 for Q4 2025.
- In Q4 2025, Cash from Operations fell 52.85% year-over-year to 35343000.0; the TTM figure through Dec 2025 stood at 131080000.0 (down 48.58% YoY), while the FY2025 annual figure was 131080000.0, down 48.58% from the prior year.
- Cash from Operations for Q4 2025 stood at 35343000.0, down from 34509000.0 in the prior quarter.
- The five-year high for Cash from Operations was 6580000.0 in Q2 2021, with the low at 35343000.0 in Q4 2025.
- The 5-year median for Cash from Operations is 12708500.0 (2022), against an average of 17667000.0.
- The sharpest annual moves came in 2021 and 2024: Cash from Operations rose 13.9% in 2021, then plunged 90.26% in 2024.
- Cabaletta Bio's Cash from Operations stood at 10515000.0 in 2021, then declined by 15.37% to 12131000.0 in 2022, then slumped by 35.59% to 16448000.0 in 2023, then sank by 40.58% to 23122000.0 in 2024, then tumbled by 52.85% to 35343000.0 in 2025.
- Business Quant data shows CABA's Cash from Operations at 35343000.0 in Q4 2025, 34509000.0 in Q3 2025, and 30426000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Cabaletta Bio | 466.25 Mn | 466.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -35.34 Mn |
| Dec 31, 2025 | -35.34 Mn |
| Sep 30, 2025 | -34.51 Mn |
| Sep 30, 2025 | -34.51 Mn |
| Jun 30, 2025 | -30.43 Mn |
| Jun 30, 2025 | -30.43 Mn |
| Mar 31, 2025 | -30.80 Mn |
| Mar 31, 2025 | -30.80 Mn |
| Dec 31, 2024 | -23.12 Mn |
| Dec 31, 2024 | -23.12 Mn |
| Sep 30, 2024 | -20.32 Mn |
| Sep 30, 2024 | -20.32 Mn |
| Jun 30, 2024 | -20.79 Mn |
| Jun 30, 2024 | -20.79 Mn |
| Mar 31, 2024 | -23.99 Mn |
| Mar 31, 2024 | -23.99 Mn |
| Dec 31, 2023 | -16.45 Mn |
| Dec 31, 2023 | -16.45 Mn |
| Sep 30, 2023 | -12.60 Mn |
| Sep 30, 2023 | -12.60 Mn |